PD-1 Sponsors Expand Into Bladder, Head & Neck Cancer

Merck claims first Phase III survival data in bladder cancer for Keytruda, while Bristol shows potential for immunotherapy combinations in bladder and head and neck cancers at the annual SITC meeting.